Ynke Larivière, Trésor Zola Matuvanga, Bernard Isekah Osang'ir, Solange Milolo, Rachel Meta, Primo Kimbulu, Cynthia Robinson, Michael Katwere, Chelsea McLean, Gwen Lemey, Junior Matangila, Vivi Maketa, Patrick Mitashi, Jean-Pierre Van Geertruyden, Pierre Van Damme, Hypolite Muhindo-Mavoko
BACKGROUND: Health-care providers and front-line workers are at risk of contracting Ebola virus disease during an Ebola virus outbreak and consequently of becoming drivers of the disease. We aimed to assess the long-term immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen and the safety of and immune memory response to an Ad26.ZEBOV booster vaccination at 1 year or 2 years after the first dose in this at-risk population. METHODS: This open-label, single-centre, randomised, phase 2 trial was conducted at one study site within a hospital in Boende, Democratic Republic of the Congo...
March 26, 2024: Lancet Infectious Diseases